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Abstract
Expression of galectin-3 is associated with sarcoma progression, invasion and metastasis. Here we determined the role of
extracellular galectin-3 on migration of sarcoma cells on laminin-111. Cell lines from methylcholanthrene-induced sarcomas
from both wild type and galectin-3
2/2 mice were established. Despite the presence of similar levels of laminin-binding
integrins on the cell surface, galectin-3
2/2 sarcoma cells were more adherent and less migratory than galectin-3
+/+ sarcoma
cells on laminin-111. When galectin-3 was transiently expressed in galectin-3
2/2 sarcoma cells, it inhibited cell adhesion and
stimulated the migratory response to laminin in a carbohydrate-dependent manner. Extracellular galectin-3 led to the
recruitment of SHP-2 phosphatase to focal adhesion plaques, followed by a decrease in the amount of phosphorylated FAK
and phospho-paxillin in the lamellipodia of migrating cells. The promigratory activity of extracellular galectin-3 was
inhibitable by wortmannin, implicating the activation of a PI-3 kinase dependent pathway in the galectin-3 triggered
disruption of adhesion plaques, leading to sarcoma cell migration on laminin-111.
Citation: Melo FHM, Butera D, Junqueira MdS, Hsu DK, Moura da Silva AM, et al. (2011) The Promigratory Activity of the Matricellular Protein Galectin-3 Depends
on the Activation of PI-3 Kinase. PLoS ONE 6(12): e29313. doi:10.1371/journal.pone.0029313
Editor: Ben C.B. Ko, Chinese University of Hong Kong, Hong Kong
Received February 11, 2011; Accepted November 25, 2011; Published December 28, 2011
Copyright:  2011 Melo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was funded by Fundac ¸a ˜o de Amparo a Pesquisa do Estado de Sa ˜o Paulo (FAPESP-Proc. 98/14247–6) and Conselho Nacional de
Desenvolvimento Cientı ´fico e Tecnolo ´gico (CNPq). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rchammas@lim24.fm.usp.br
Introduction
Activation of the migratory and invasive capacities by tumor
cells are often associated with tumor progression [1]. Central to
these changes are alterations in either the expression pattern or
activity of integrins, key regulators of the organization of
cytoskeleton, cell adhesion and survival [2]. RAS pathway
activation promotes invasiveness and metastatic spread in different
cancers, including sarcomas. We have previously shown that EJ-ras
expressing NIH-3T3 fibroblasts acquired the ability to migrate on
laminin-111 surfaces [3,4]. Although fibroblasts are highly
migratory cells, this is usually true for the migration elicited by
interstitial extracellular matrices composed mainly of collagen I
and III and fibronectin. Migration on laminin is considered a
dysfunctional pattern of migration for fibroblasts [5]. We showed
that this pattern was dependent on the expression of a6b1 integrin,
whose expression is up-regulated after transfection with activated
ras. Not only the expression of the integrins is altered upon
transformation, but their pattern of glycosylation also varies [6].
Integrins in transformed cells tend to accumulate tri- and
tetraantennary N-linked oligosaccharides recognized by the plant
lectin leucoagglutinin from Phaseolus vulgaris (L-PHA) [7–9]. These
N-linked glycans may present polylactosamine structures, which
are among the glycans recognized by the animal lectin, galectin-3
[10–12].
Galectin-3 is the only chimeric member of the family of
galectins [13]. It is a 29–35 kDa protein which has a unique
amino-terminal domain involved in the translocation of galectin-3
within different cellular compartments [14], a proline, glycine and
tyrosine rich region and a carbohydrate recognition domain
(CRD) in the carboxy-terminal region. Galectin-3 is mainly a
cytoplasmic protein that can translocate into the nucleus,
mitochondria and it can even be secreted [15–17]. Ochieng and
colleagues demonstrated that while detached and spherical cells
secrete galectin-3 constitutively, attached and spread cells take
galectin-3 up from the conditioned medium [18]. These results
support the notion that mechanotransductional signals may be
involved in galectin-3 secretion. In the extracellular space,
galectin-3 binds to a variety of extracellular matrix components
like laminin, fibronectin, hensin, elastin, collagen IV and tenascin-
C and -R [19], modulating cell-matrix dependent biological
processes, such as adhesion and migration, in normal and cancer
cells. In this context, galectin-3 has all features of a matricellular
protein [20].
In cancers, galectin-3 expression is dependent on the tumor
histogenesis [20,21]. An increase in galectin-3 expression has been
reported in lymphomas, head and neck and thyroid carcinomas,
glioblastomas and osteosarcomas [20,22–25]. In contrast, down-
regulation of galectin-3 expression has been reported in breast and
prostate cancer [26,27]. Changes in galectin-3 expression have
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29313also been observed in colon cancer [28,29]. Accumulation of
galectin-3 in transformed highly migratory fibroblasts and invasive
osteosarcomas [4,22,28,29] prompted us to investigate its possible
role as a modulator of integrin function in tumor cells of
mesenchymal origin.
Here we have addressed the role of galectin-3 in the adhesive
and migratory properties of methylcholanthrene-induced sarco-
ma-derived cells from both galectin-3
+/+ and galectin-3
2/2 mice
on laminin-111 substrata. We showed that galectin-3 decreased
cell adhesion and promoted cell migration. Furthermore, addition
of extracellular galectin-3 to galectin-3
2/2 cells induced recruit-
ment of SHP-2 phosphatase to and loss of phosphorylated FAK
and phospho-paxillin from focal complexes. The promigratory
activity of extracellular galectin-3 was associated with AKT
phosphorylation, and it was PI3-kinase dependent, since it could
be inhibited by wortmannin.
Results
Cytoplasmic galectin-3 is recruited to the leading edge of
migrating cells
In a previous report [4], we have shown that EJ-ras expressing
NIH3T3 cells (CCR2 cells) acquired the ability to migrate on
laminin-111 surfaces, characterizing a dysfunctional pattern of
migration. Migration on laminin-111 is dependent on a6b1
integrins, whose expression is up-regulated in CCR2 cells.
Subcellular localization of galectin-3 in migrating CCR2 cells
was analyzed as shown in Fig. 1, using M3/38 monoclonal
antibody, whose epitope maps within residues 48–100 in the
amino-terminal domain of galectin-3 [30]. Migrating cells
displayed galectin-3 in the lamellipodia, as indicated by arrows
in the illustrative Fig. 1. We have also previously shown that
experimental sarcomas expressed galectin-3, galectin-3 ligands and
acquired the capacity of migrating onto basement membranes of
muscle fibers, a commonly observed feature of locally invasive
sarcomas [12]. Altogether these results suggest the involvement of
galectin-3 in the acquisition of the dysfunctional migration pattern
of sarcoma cells on basement membrane proteins, such as laminin.
Establishment and characterization of sarcoma-derived
cell lines from both wild type and galectin-3
2/2 mice
In order to investigate the role of galectin-3 in dysfunctional
migration of sarcoma cells, sarcoma-derived cell lines from both
wild type and galectin-3
2/2 mice were established. Sarcomas were
chemically induced by subcutaneous injections of methylcholan-
threne [31]. As shown in Fig.2A, treatment of either wild type
C57Bl/6 mice (n=23) or galectin-3
2/2 mice (n=17) with two
subcutaneous injections of methylcholanthrene (50 mg/animal/
dose within a 12-week interval) led to the generation of palpable
tumors within 7 months. A significant difference in the number of
tumor-bearinganimalsafter7monthswasobserved.Galectin-3
2/2
mice tended to be more resistant to the development of tumors.
Histopathological analysis showed that all tumors were sarcomas
(Fig. S1). Sarcomas from both wild type and galectin-3
2/2 mice
were cultured and three independent cell lines were obtained, S11
and S12 (derived from sarcomas of wild type mice) and S12
(derived from a galectin-3
2/2 sarcoma). Galectin-3 was found
only in extracts of earlier passages of S11 cells. On the other hand,
S12 cells maintained the expression of galectin-3 regardless of their
passage number (Fig. 2B). The two bands present in S12 cell
extracts are often found in these and other cellular extracts. A
possible explanation for the lower apparent molecular weight band
is cleavage of the amino-terminus region of galectin-3. This
apparently cleaved form is also found in recombinant galectin-3
(see reference [30], for an example). The precise nature of the
protein modification which yields the second band is currently
under investigation in our laboratory. As expected, S12 cells did
not express galectin-3 (Fig. 2B). Galectin-3 was found on the
membrane of S11 cells (Fig. 2C). Similar results were observed for
S12 cells (data not shown). All three clones displayed similar levels
of both a6 and b1 integrin chains on the cell surface (Fig. S2). The
a6b1 integrin was functional and mediated sarcoma cell adhesion
and migration on laminin-111 (data not shown).
Galectin-3 modified the adhesion and migration pattern
of sarcoma-derived cell lines on laminin-111
Both S11 and S12 cells adhered less on laminin-111 surfaces
than S12 cells (Fig. 3A and data not shown). On the other hand,
S12 were less migratory than S11 and S12 cells on laminin-111
substrata (Fig. 3B and 3C), indicating that galectin-3 modulated, at
least in part, the interaction of sarcoma cells with laminin-111.
Lactose inhibited significantly the laminin-induced migration of
S11 cells (Fig. 3C).
S12 cells were then transiently transfected with galectin-3 in
order to determine whether the migratory phenotype of galectin-3
expressing sarcoma cells could be restored. No changes in b1
integrin expression were observed in the transfected cells (neo,
control; neo/gal 3, galectin-3 expressing cells) (Fig. S3). Galectin-3
expression in S12 cells transfected with neo/gal 3 was demon-
strated by western blotting (Fig. 3D). The expression level of
galectin-3 was estimated as a tenth of the amount expressed by
S12 cells, thus indicating that the transgene expression was not
associated with accumulation of aberrant levels of galectin-3.
Adhesion of galectin-3 expressing S12 cells on laminin had a 2.5-
fold decrease, as compared to the control transfectants (Fig. 3E).
Concomitantly, galectin-3 expressing S12 cells were more
migratory in response to laminin-111 than the parental cells
(Fig. 3E). The migratory response was clearly dependent on
extracellular galectin-3, since it could be inhibited by exogenous
lactose, but not sucrose (Fig. 3E). Transient transfection of
galectin-3 gene in S11 cells also led to an increase in their
migratory response to laminin-111 (Fig. 3F). To evaluate the role
of extracellular galectin-3 in the migratory response of sarcoma
cells, migration of galectin-3 null S12 cells was studied either in
the absence or presence of exogenous recombinant galectin-3
(Fig. 3G). The migratory response of sarcoma cells to extracellular
galectin-3 was dose-dependent (Fig. S6). Laminin-111 induced
migration was evaluated using the scrape assay. In the absence of
galectin-3, differences in migration were not statistically signifi-
cant. A robust and significant increase in cell migration was
observed when cells were exposed to galectin-3. This increase was
inhibited in the presence of lactose, reconfirming the notion that
the effect of galectin-3 on cell migration depended upon its lectin
activity.
Extracellular galectin-3 induced the disassembly of focal
adhesion plaques
Cell migration is a complex process that depends on a precisely
orchestrated series of events involving adhesion, deadhesion and
rearrangements of the cytoskeleton. Signals are processed at focal
contact points, supramolecular structures formed upon ligation
and clustering of integrins followed by the recruitment of specific
proteins [32,33]. To investigate the mechanisms underlying
galectin-3-induced cell migration, we examined the levels of
tyrosine phosphorylation of proteins involved in focal adhesion
turnover. We analyzed the effects of extracellular galectin-3 on the
organization of focal adhesion plaques in the galectin-3
2/2 S12
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phosphorylated FAK form organized stress fibers (Fig. 4, ctl
panels and Fig. S4). When cells are stimulated to migrate, these
structures are disassembled and the cytoskeleton is reorganized,
thus allowing cell movement. Using the scrape assay, we followed
laminin-induced cell migration either in the absence (LN) or
presence of galectin-3 (LN+gal-3) for 15 minutes, as illustrated in
Fig. 4. Exposure of cells to extracellular galectin-3 resulted in a
significant decrease in the amount of phosphorylated FAK in cell
protrusions, followed by an extensive reorganization of cytoskeletal
actin and membrane ruffling as compared to control conditions
(ctl or LN) or cells exposed to galectin-3 in the presence of lactose
(LN+gal-3+lac) (Fig. S4).
The Src homology 2 domain-containing protein tyrosine
phosphatases SHP-2 dephosphorylate FAK and paxillin [34,35].
The decrease in the amount of phosphorylated FAK in the
lamellipodia of migrating cells exposed to extracellular galectin-3
for 15 minutes was associated with the recruitment of the tyrosine
phosphatase Shp-2 to the focal complexes, as shown in Fig. 5B.
Paxillin is another important focal adhesion molecule that is
associated with and phosporylated by FAK [36,37]. To explore
whether paxillin phosphorylation was also regulated by galectin-3
treatment, phospho-paxillin levels were measured after exposure
of galectin-3. As shown in Figure 5C, as seen for FAK
phosphorylation (Fig. 4), galectin-3 mediated a decrease in paxillin
phosphorylation levels. Intriguingly, in the presence of the
proteasome inhibitor lactacystin, there was an increase in the
amount of phosphopaxillin after exposure of cells to galectin-3.
Galectin-3 activates PI-3 kinase signaling
In addition to acting as an adaptor protein, interacting and
recruiting multiple target proteins to focal adhesion complexes,
FAK modulates signaling pathways as those triggered by the Rho
family, which coordinates cellular processes such as adhesion,
migration and actin cytoskeleton reorganization [38]. Rac1 is a
member of the Rho family of small GTP-ases and plays a
fundamental role in actin cytoskeleton reorganization, lamellipo-
dia formation, and cell migration [38]. Rac1 interacts with specific
effectors, including p21 activated kinases (PAK) [39]. Exposure of
corneal epithelial cells to galectin-3-activated Rac1, increasing
their migratory capacity [40]. To determine whether galectin-3
induced the activation of Rac1-dependent signaling pathways in
sarcoma cells, we evaluated whether phosphorylated PAK
accumulated in focal contacts upon exposure to galectin-3. PAK
was not found in focal contacts and remained in the cytoplasm of
S12 cells exposed to galectin-3 (Fig. S5). Alternatively, it was
shown that Rac1 can activate PI-3 kinase signaling in epithelial
cells and its activation is sufficient to disrupt epithelial polarization
and induces cell motility and invasion [41]. Migrating cells
exposed to galectin-3 showed increased AKT phosphorylation
levels (Fig. 6A) and inhibition of PI-3 kinase dependent pathway
using wortmannin abolished the promigratory activity of galectin-
3 (Fig.6B), indicating that galectin-3 acts as a positive modulator of
laminin-111-induced cell migration via a PI-3 kinase dependent
pathway.
Figure 1. Galectin-3 is found on the lamellipodia of migrating
fibroblasts. CCR2 cells were subjected to the scrape assay. The cells
were grown in coverslips to confluence, when a wound was made. The
cells were maintained in culture for additional 24 hours, when it was
possible to observe cells migrating into the wounded area. Panels show
the distribution of galectin-3, which was detected with galectin-3
monoclonal antibody M3/38, followed by incubation with a rhodamine-
conjugated secondary antibody. Galectin-3 is localized in the cytoplasm
of the cells and also in leading edge of migrating cells as indicated by
arrows.
doi:10.1371/journal.pone.0029313.g001
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Here we have provided evidence for the involvement of
extracellular galectin-3 as a positive modulator of sarcoma cell
migration on laminin-111. De novo expression of galectin-3 in a
galectin-3
2/2 sarcoma cell line decreased its adhesion and
promoted its migratory capacity on laminin-111, in a carbohy-
drate-dependent manner. Modulation of migration was associated
with the recruitment of Shp2 tyrosine phosphatase to focal
complexes and an apparent acceleration of FAK and paxillin
turnover on focal contacts, as evaluated by the decrease of
phosphorylated-FAK in lamellipodia of migrating cells and
paxillin in focal complexs. Migrating sarcoma cells presented
increased phosphorylation levels of AKT and the promigratory
activity of galectin-3 was inhibited by wortmannin, indicating its
dependence on the activation of PI-3 kinase pathways.
Accumulation of galectin-3 upon transformation of cells that do
not express this lectin under physiological conditions has been
observed in different models of tumor progression [42,43].
Accumulation of galectin-3 is associated with malignant transfor-
mation of fibroblasts and other mesenchyme-derived cells [43–45].
Khanna and colleagues (2001) have shown that galectin-3
accumulates in more metastatic osteosarcoma cells, thus providing
an association between galectin-3 expression and a more invasive
phenotype. In sarcoma cells, such as CCR2 cells which express
high amounts of galectin-3, migrating cells display a significant
amount of the lectin in the lamellipodia, as illustrated in Fig. 1.
Galectin-3 accumulation in different cell types within specialized
tissue microenvironments have been associated with the acquisi-
tion of a migratory phenotype. We and others showed that
galectin-3 was found overexpressed in glioblastomas [23,46],
especially within pseudopalisades, which are formed by migrating
cells surrounding necrotic areas [47]. In the thymus, galectin-3 is
produced by stromal cells. We have previously shown that
galectin-3 could impair integrin-dependent intercellular interac-
tions between thymocytes and thymic epithelial cells [48], leading
to migration of CD4
+CD8
+ thymocytes [49]. Galectin-3 modu-
lates the formation of focal contacts composed by laminin-332,
a3b1 and a6b4 integrins promoting keratinocyte motility [50].
Taken together, these data strongly suggest that extracellular
galectin-3 plays an important role in the control of adhesion and
migration.
Figure 2. Galectin-3
2/2 mice are more resistant to methylcholanthrene induced sarcomas development. Wild type and galectin-3
2/2
mice were given two subcutaneous doses of 3-methylcholanthrene, a known chemical carcinogen. The development of tumors was followed weekly
after the second dose. Analysis of the disease-free survival curves from both wild type (n=23 animals) and galectin-3
2/2 mice (n=17 animals)
showed that wild type mice developed sarcomas faster than galectin-3
2/2 animals (A)( Log-rank test, p=0.04). At necropsy, tumors were maintained
in culture conditions, allowing for the establishment of sarcoma derived cell lines. Galectin-3 accumulation was analyzed in protein extracts from
established cell lines from both wild type (S11 and S12) and galectin-3
2/2 mice (S12) by western blotting. S11 and S12 cells, but not S12 cells,
expressed galectin-3. While S12 cells maintained high expression of galectin-3 in all passages analyzed, only early (e, passage number,15), but not
late (l, passage number.15) passages of S11 expressed galectin-3. Note that part of the molecules produced were further processed rendering the
lower molecular weight form of the lectin, which appears as a 30 kDa band (B). The expression of galectin-3 on S11 and S12 cell surface was analyzed
by flow cytometry. S11 cells display at least part of its galectin-3 content on the cell surface (C).
doi:10.1371/journal.pone.0029313.g002
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2/2 cell line is more adherent and less migratory on laminin-111 surfaces. S12 cells were compared to S12 cells
regarding their adhesive (panel A) and migratory capacity (panel B). For the adhesion assay (panel A), each point represents the mean of
triplicates, SD is also represented. The migratory capacity of S12 and S12 cells on laminin-111 was evaluated using Transwell chambers (panel B).
Migration assays were also performed comparing S11 and S12 cells, as described in B. In these assays, lactose was used to inhibit cell migration. S11
cell migration, but not S12 cell migration was inhibited by lactose. Migration of S11 cells without lactose inhibition was used as internal reference for
determining relative migration (panel C). S12 cells were transiently transfected with either a plasmid containing the galectin-3 gene or a control
plasmid. While no galectin-3 was found in S12 cells transfected with the control plasmid (neo) expression of galectin-3 was observed in neo/gal-3
transfected cells by western blotting. Extracts of S11 and S12 cells used were used as positive controls (panel D). S12 cells were rendered less
adherent and more migratory upon transfection with pEF1-neo/gal-3. Relative adhesion was determined based on the adhesion of neo-transfected
Galectin-3 as a Matricellular Protein
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galectin-3 and the protein is displayed on the cell surface (Fig. 2B
and 2C). Despite the lack of a classical signal peptide for secretion,
galectin-3 can be transferred to the extracellular space, via a non-
classical pathway [51,52]. The ability of galectin-3 to cross the
lipid bilayer of large unilamellar vesicles suggests that this lectin
has an yet to be identified signal sequence, or posttranslational
modification, that enables it to interact and traverse the plasma
membrane [53]. Once secreted, galectin-3 interacts with extra-
cellular matrix proteins/glycoproteins and their receptors [40,54–
56]. Exposure of cells to galectin-3 ligands, such as fetuin, induced
secretion of galectin-3 [57]. Since laminin-111 is also a galectin-3
ligand, it is conceivable that exposure of cells to laminin would
induce local secretion of galectin-3. Recruitment of galectin-3 to
the lamellipodia could be a first step towards its vectorial secretion,
as illustrated in Fig. 1. Besides secretion, galectin-3 could be
released into the extracellular space following cell lysis, which does
occur in tumor microenvironments, for example. Release [57] of
galectin-3 from necrotic cells may have an impact on tissue repair,
as it is a potent chemoattractant for leukocytes [16,58] and some
epithelial cells [59]. Most chemoattractants lead to the inside-out
activation of integrins [60]. In the case of galectins, integrins are
also putative ligands for galectin-3, suggesting the existence of an
alternative outside-in pathway that could lead to modulation of the
integrin function [40,61].
Our results showed that extracellular galectin-3 led to a de-
adhesion state, what has been shown in different cellular models in
vitro [48,55,62] and in vivo [40,49]. Considering the possibility of a
polarized secretion of galectin-3 at the cell leading edge, this de-
adhesive state could contribute to cell migration, as galectin-3 led
to the destabilization of focal complexes. We also showed that
galectin-3 led to the recruitment of SHP-2 tyrosine phosphatase
and to a decrease in the amount of phosphorylated FAK in focal
adhesion plaques, suggesting an acceleration of the turnover of
FAK in these structures. Recent elegant studies have implicated
galectin-3 in the disassembly of focal adhesion complex
[32,40,63,64], however in the models studied the absence of a
galectin-3 induced lattice was associated with reduced phosphor-
ylation of FAK. It is important to point out that the role of FAK in
promoting either cell motility or invasion is through the activation
of different signaling pathways [65], therefore it may not be
possible to predict just by the state of phosphorylation of FAK
whether cells would adhere strongly or migrate. FAK has been
implicated in growth-factor-induced cell motility through dephos-
phorylation and inactivation upon stimulation of growth factor
receptors in a variety of human tumor cells, suggesting that
dephosphorylation of adhesion-related proteins may be a common
event associated with tumor migration and invasion. EGF and
IGF-1-receptor induced migration and invasion is also associated
with dephosphorylation of FAK, p130
cas and paxillin [66]. In
agreement with the phenomenon observed in sarcoma cells, Pierce
and colleagues showed that knocking down of MGAT5 expres-
sion, which led to decreased synthesis of galectin-3 ligands in
molecules such as the EGFR, interfered with the migratory
response of breast cancer cells in response to EGF. The EGF-
induced migratory phenotype is associated with activated SHP-2,
dephosphorylation of FAK and accelerated turnover of focal
adhesion contacts [67]. We have also observed a decrease in the
amount of phosphorylated paxillin upon exposure of sarcoma cells
to galectin-3. In this particular case, decreased amounts of
phosphorylated paxillin was associated with proteasomal activity,
as treatment of cells with lactacystin restored the amount of
phosphorylated paxillin to control levels. Regardless, exogenous
galectin-3 led to decreased phosphorylation of FAK and loss of
phosphorylated paxillin from the focal adhesion complexes,
favoring sarcoma cell migration. Interestingly, cell adhesion to
other matricellular proteins, such as tenascin and SPARC, also
triggered paxillin tyrosine dephosphorylation [68].
FAK can trigger activation of small GTPases, such as Rac and
Cdc42, that regulate extension of filopodia and lamellipodia at the
leading edge and the formation of focal adhesion complexes
during cell migration [38]. The best characterized effector of Rac
and Cdc42 that mediates cell motility is p21-activated kinase
(PAK) [38]. Galectin-3 does not lead to PAK phosphorylation and
recruitment to focal adhesion complexes, suggesting the involve-
ment of another signaling pathway in the migratory response of
sarcoma cells to galectin-3. There is evidence that Rac and Cdc42
can regulate cell migration through activation of the PI-3 kinase
signaling pathway [41,69]. This is the case of the sarcoma cells
studied herein, since exposure to galectin-3 led to a significant
increase in phospho-AKT levels and wortmannin inhibited the
promigratory activity of galectin-3. Likewise, in other mesenchy-
mal cells, such as smooth muscle cells, IGF-1-triggered migration
depends on the activation of SHP-2, which in turn leads to the
activation of PI-3 kinase [70].
Altogether, our results indicate that extracellular galectin-3 acts
as a matricellular protein [71], like tenascin-C [72], thrombos-
pondin [73], SPARC [74], and galectin-8 [75]. It is tempting to
speculate that through its binding to integrins or integrin-
associated molecules, galectin-3 interferes with the structural
organization of platforms containing the ECM receptors. As it is
demonstrated, galectin-3 tends to oligomerize when bound to its
ligands [76], therefore galectin-3 and their ligands may form a
lattice on the cell surface, as suggested by Dennis and colleagues
[77–79]. This lattice may justify the enrichment of galectin-3 on
focal adhesion complexes, as we have observed in S12 cells
exposed to exogenous galectin-3. The ratio between the amount of
extracellular galectin-3 and their ligands in the extracellular matrix
and on the cell surface dictates the structure of this molecular
lattice. Density of signal transducing molecules in very close
proximity within the supramolecular structure of these lattices
would determine cell responses, such as adhesion or migration.
Identification and recruitment dynamics of the proteins present in
these supramolecular structures is now warranted.
cells. Cell migration was evaluated in Transwell chambers, whose filters were coated with laminin-111. The transfected S12 cells were incubated in
serum-free medium either in the absence or presence of the indicated concentrations of lactose or sucrose. Migration of the former cells towards
laminin-111 was inhibited by lactose, but not by sucrose, indicating a role for galectin-3 in the modulation of cell migration in response to laminin-
111 (panel E). S11 cells were transiently transfected with pEF1-neo or pEF1-neo/gal-3 and checked for their migratory response towards laminin-111
in Transwell chambers. A significant increase in the migratory response elicited by laminin-111 was observed in S11 cells overexpressing galectin-3.
Migration of neo-transfected S11 cells was used as internal reference for determining relative migration (panel F). The migratory capacity of S12 cells
was evaluated in absence or presence of extracellular galectin-3 (gal-3), laminin-111 (LN) and in the presence or absence of 100 mM lactose (Lac) for
24 hours using the scrape assay. Exogenous galectin-3 increased the migration of S12 cells when soluble LN was added, such increase was inhibited
by lactose. Migration of S12 cells in the presence of both LN and galectin-3 was used as internal reference for determining relative migration (panel
G). In all panels, results are representative of at least three independent assays. Means and SD are represented. White bars represent results from
galectin-3 expressing cells; black bars represent results from galectin-3 null cells.
doi:10.1371/journal.pone.0029313.g003
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Ethics Statement
All animal work conducted during this project was approved by
the Ethics Committee of Faculdade de Medicina da Universidade
de Sa ˜o Paulo, which followed the guidelines of the American
Association of Veterinary Medicine. All animal manipulations
were performed by trained personnel. Tumor bearing animals
were euthanized when the larger tumor diameter reached 1 cm,
using IP injection of anesthetics.
Reagents
Unless otherwise stated, reagents were purchased from Sigma
(St. Louis, MO). Rat anti-a6 GoH3 was purchased from Coulter
(Marseille, Fr) and FITC-conjugated anti-CD29 was from
Pharmigen (San Diego, CA). Mouse anti-P-FAK was purchased
from Chemicon (Temecula, CA). Rabbit anti-FAK and anti-SHP2
antibodies were purchased from Santa Cruz Biotechnology, INC
(Santa Cruz, CA). Rabbit anti-mouse AKT and anti-P-AKT were
purchased from Cell Signaling Technologies (Danver,MA). Rabbit
anti-rat IgG horseradish peroxidase-conjugated antibodies were
purchased from KPL- Kirkegaard & Perry Laboratories (Gai-
thersburg, MD). Laminin-111 was kindly provided by Dr. Vilma
Martins (Ludwig Institute for Cancer Research, Sa ˜o Paulo).
Animals
Both galectin-3
2/2 (Gal-3
2/2) and wild type C57bl/6 (Gal-3
+/+)
mice came from F.-T. Liu’s laboratory and were generated as
described elsewhere [80]. Mice were housed under conventional
conditions approved by the University of Sa ˜o Paulo-Medical School
Ethics committee and local animal research facility. Six to eight
week old animals were used in all the experiments.
Induction of sarcomas
Both wild type and galectin-3
2/2 mice were given two
subcutaneous injections of 50 mg of methylcholanthrene in
tricapriylic oil. The first dose was given to 6–8 week old mice,
the second dose was given twelve weeks after and the development
of tumors was then followed weekly. When tumors reached 0.5–
1c m
3, mice were sacrificed under aseptic conditions, and tumors
were dissected, minced into small fragments (0.01–0.05 cm
3),
which were maintained in culture. Part of tumor fragments were
fixed in phosphate-buffered paraformaldehyde and then processed
for routine histopathology.
Cells and Culture conditions
The murine cell lines S11, S12 e S12 were established from the
explanted methylcholanthrene-induced sarcomas. The S12 cell
line was derived from a galectin-3
2/2 background, while both S11
and S12 cell lines were derived from the wild type genotype. The
CCR2 cell line was established by transformation of NIH3T3
fibroblasts with an activated form of EJ-ras, as described elsewhere
[4]. The hybridoma TIB-166/M3-38 (American Tissue Culture
Collection), which secretes a rat monoclonal antibody against
galectin-3, was cultured in RPMI 1640 supplemented with 20%
fetal calf serum.
Transient transfection
S11 and S12 cells were transiently transfected with either
pEf1neo or pEf1neo-gal3 using Lipofectamine
TM (GIBCO BRL,
Grand Island, NY), according to the manufacturer’s protocol.
After 24–72 h, transfected cells were checked for the expression of
the transgene by western blotting and used in the assays described
below. Transfection efficiency was typically around 15% of cells.
Western blotting
Protein extracts were prepared using lysis buffer (1% Triton
X2100 in 150 mM NaCl and 50 mM Tris pH7.4 , containing
5 mM EDTA, 2 mg/mL aprotinin and 1 mM PMSF) and kept at
Figure 4. Extracellular galectin-3 (Gal-3) promotes the disas-
sembly of stable focal adhesion plaques by decreasing the
amount of phosphorylated FAK in the lamellipodia of migrat-
ing cells. S12 cells were grown on coverslips and were subjected to
the scrape assay either in the absence (ctl) or presence of laminin-111
(LN) or laminin-111 and 20 mg/mL galectin-3 (LN+gal-3) for 15 minutes.
Cells were either fixed after 15 minutes after the migration stimulus.
Confocal photomicrographs of typical fields are shown. Intracellular
distribution of phosphorylated FAK (green) and organization of stress
fibers (phalloidin staining, in red) are shown. Control cells showed
mature adhesion plaques, as shown by staining of phosphorylated FAK.
In the presence of galectin-3, there was a fast disassembly of the
adhesion plaques indicated by the decrease of phosphorylated FAK in
the lamellipodia.
doi:10.1371/journal.pone.0029313.g004
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SDS-sample buffer (240 mM Tris-HCl pH 6.8, 0.8% SDS,
200 mM b-mercaptoethanol, 40% glycerol and 0.02% bromo-
phenol blue) for 5 min and then separated by electrophoresis in
12.5% SDS-polyacrylamide gels and transferred to a polyvinyli-
dene difluoride membrane (Millipore Corp., Bedford, USA).
Protein loading was always confirmed in a second gel run
simultaneously and stained with Coomassie blue. After protein
transfer, the membranes were blocked with 5% nonfat dry milk in
PBS (10 mM phosphate buffer pH 7.2, 150 mM NaCl), incubated
with the indicated antibodies overnight at 4uC, followed by
incubation with appropriate secondary antibodies and develop-
ment with either diaminobenzidine, chemiluminescence assay or
further incubation with
125I-protein A.
Flow cytometry analysis
Cultured cells were harvested with trypsin and EDTA. After
trypsin inactivation, cells were washed with PBS containing 1%
BSA and incubated with different antibodies. Typically, 10
6 cells
were incubated at a final concentration of 2.5 to 4 mg/mL of anti-
integrins or anti-galectin-3 for 1 hour at 4uC. After 3 washes with
PBS containing 0.1% BSA, cells were incubated with 1 mg/mL
FITC-conjugated secondary antibodies for 1 hour at 4uC. After
washing, cells were analyzed in a flow cytometer (FACScalibur,
Becton Dickinson).
Migration assay
Migration assays were performed in Transwell chambers
(Costar, NY) essentially as described elsewhere [4]. Briefly, a
10 mg/mL solution of laminin-111 in DMEM was used to coat the
lower surface of the polycarbonate filter for 2 hours at 37uC. The
filter was then blocked with DMEM containing 1% BSA for
1 hour. After harvesting, 2x10
5 cells were suspended in 0.5 mL
DMEM and added in the upper compartment of the Transwell
chambers, either in the absence or presence of indicated
concentrations of lactose or sucrose for 2 to 4 hours at 37uC.
Filters were then washed with PBS, fixed in 3.7% formaldehyde
for 15 min, stained with toluidine blue for 5 min. Non-migrating
cells present in the upper compartment were removed with a
cotton swab. The migrating cells were counted directly, using an
inverted microscope. Every assay point was done in triplicates in
three independent experiments. At least ten distinct medium
power fields (objective x20), corresponding to a graticle-defined
area of 0.25 mm
2, were counted for each filter. Analysis was done
using ANOVA followed by the Bonferroni’s t test for multiple
comparisons, using the GraphPad Prism software.
Cell adhesion
The adhesion assay was performed essentially as described
elsewhere [7]. Briefly, 24-well cell culture clusters (Costar, NY)
were coated with increasing concentrations of laminin-111 in
DMEM overnight at 4uC. The plate was then blocked with 2%
BSA in PBS for 1 h at 37uC and washed three times with PBS.
Cells were suspended in DMEM without serum and added to each
well (10
5 cells/well). After two hours at 37uC, non-adherent cells
were washed out gently. Adherent cells were then fixed, stained as
above and counted directly using an inverted microscope, as was
done for migration assays.
Preparation of galectin-3
Recombinant human galectin-3 was produced in E. coli and
purified by affinity chromatography on lactosyl-agarose as
described previously [81], followed by extensive dialysis against
PBS pH 7.4. Galectin-3 was then concentrated by ultradiafiltra-
tion using Amicon Ultra-15 centrifugal filters (Millipore, Bedford,
MA). Galectin-3 concentration was determined by using the Bio-
Rad Dc Protein Assay (Bio-Rad Laboratories, Hercules, CA),
separated into aliquots, and stored at 220uC until use.
Effects of galectin-3 on the distribution of focal contact
proteins
S12 cells were grown in DMEM supplemented with 10% FBS
on glass coverlips to near confluence for 48 h. After 2 washes with
PBS, the cells were subjected to the scrape assay. A wound was
made and the cells were incubated with 10 mg/mL laminin-111 in
the absence or presence of 20 mg/mL galectin-3, either in the
presence or absence of 100 mM lactose, for 15 minutes in medium
under serum-free conditions at 37uC and then fixed and processed
for immunofluorescence staining. Alternatively, 5 million S12 cells
Figure 5. Analysis of proteins enriched in the focal complexes in the absence (-) or presence (+) of extracellular galectin-3. S12 cells
were exposed to 10 mg/mL laminin and 20 mg/mL galectin-3 for 15 minutes and focal complexes were then prepared and analyzed regarding the
presence of galectin-3 (A), SHP-2 (B) and phospho-paxillin (C) using Western blot analysis. (Panel A) Recruitment of galectin-3 to focal complexes
was inhibited in the presence of lactose (lane at the right in panel A). Two bands were recognized by M3/38 monoclonal antibody in focal adhesion
extracts; one which migrates with an apparent molecular weight of 30–35 kDa (Gal-3) and a second one which migrates as a 70 kDa-band (arrow). CE,
in the left lane in panels A and B refer to S12 cellular extracts. (Panels B and C) Exposure of S12 cells to extracellular galectin-3 led to an increase in
SHP-2 (panel B) and decrease of phosphorylated paxillin in the focal complexes (panel C). Prior inhibition of proteasome with lactacystin abrogated
the decrease of phosphorylated paxillin in focal complexes. Representative blot of paxillin and phosphorylated paxillin are shown and the
densitometric analysis of two independent experiments were performed, yielding similar results.
doi:10.1371/journal.pone.0029313.g005
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or not to 10 mg/mL laminin-111 and 20 mg/mL extracellular
galectin-3 for 15 minutes. Alternatively, S12 cells were treated or
not with 20 mg/mL MG132 or 5.3 mg/mL Lactascystin for four
hours and after exposed or not to 10 mg/mL laminin-111 and
20 mg/mL extracellular galectin-3 for 15 minutes. After these time
periods, focal adhesion plaques were isolated following the
protocol proposed by Avnur and Geiger [82]. Briefly, cells were
washed twice in the washing buffer (5.5 mM glucose, 5.4 mM
KCl, 137 mM NaCl, 0.4 mM KH2PO4, 0.4 mM Na2HPO4.H2O,
4 mM NaHCO3, 3.2 mM PIPES, 1.9 mM MgCl2 and 0.5 mM
CaCl2, pH 6.1), and then incubated with 0.2% saponin in the
washing buffer for 5 min at room temperature. Cell bodies were
then removed by gently flushing with the washing buffer using a
syringe. After removal of all cell bodies, controlled by direct
visualization using an inverted microscope, the extraction buffer
(8 M urea, 1 mM Tween 20 and 100 mM DTT) was then added
to the plate. After 5 minutes, the extract was collected and kept
frozen at 220uC until use.
Scrape assay
Cells were grown on glass coverslips until confluence when a
scratch wound was made [83]. Cells were then washed and
maintained in culture for 15 minutes in serum-free medium, in the
presence of exogenous laminin-111 (10 mg/mL) and galectin-3
(20 mg/mL) either in the presence of lactose (100 mM) or
wortmannin (1 mM) as indicated in the results session. The cells
were then fixed with 1% paraformaldheyde in PBS for 15 min,
permeabilized with 0.03% saponin in PBS for 15 min, and then
processed according to the aim of the assay. For experiments
aiming at quantifying migrating cells into the wounded area, cell
nuclei were stained with DAPI and counted using a fluorescence
microscope, essentially as described above. Relative migration was
calculated for each experimental group. Analysis was performed
using one-way ANOVA, followed by the Bonferroni’s t test for
multiple comparisons. For assays aiming at the analysis of focal
adhesion plaques, fixed cells were incubated with 1% BSA in PBS
for 1 hour in order to block nonspecific interactions with
immunoconjugates. The cells were then incubated with the
indicated antibodies and suitable fluorochrome-conjugated sec-
ondary antibodies or with rhodamine-conjugated phalloidin.
Coverslips were mounted on slides using a solution containing
glycerol and anti-fading agents and analyzed by either conven-
tional fluorescence or confocal microscopy, as indicated. For FAK
staining, the fixation buffer contained 4% paraformaldehyde in
0.1 M phosphate buffer, pH 7.4 containing 10 mM PIPES, 5 mM
EGTA, 2 mM MgCl2 and 0.1% Triton X2100. For galectin-3
staining was used the TIB-166/M3–38 antibody. Cells were fixed
at room temperature for 15 min, washed and then post-fixed with
95% ethanol at –20uC for 5 min.
Supporting Information
Figure S1 Histopathological analysis showed that tu-
mors from wild type (A) and galectin-3
2/2 mice (B) were
sarcomas.
(TIF)
Figure S2 S11, S12 and S12 cells display a similar
pattern of a6 and b1 integrin, the sarcoma laminin
binding integrin chains, on cell surface. Levels of laminin-
111 binding integrin on S11, S12 and S12 cell surface were
determined by flow cytometry. a6 and b1 integrin levels were
similar in all three cell lines.
(TIF)
Figure 6. Galectin-3 increases S12 cell motility through a PI-3
kinase dependent pathway. (A) S12 cells were exposed to 10 mg/
mL laminin-111 either in the absence or presence of 20 mg/mL galectin-
3 and of the proteasome inhibitor MG-132 for 15 minutes and phospho-
AKT was analyzed using Western blot analysis. Extracellular galectin-3
leads to increase of phosphorylated AKT. Representative blot of AKT
and phosphorylated AKT are shown and the densitometric analysis of
two independent experiments were performed. (B) S12 cells were
grown in coverslips and subjected to the scrape assay. Migration of S12
cells into the scratched area was measured after 24 hours by direct
counting of DAPI-stained cells using a graticle projected onto
micrographs collected using a fluorescence microscope. Cells were
incubated or not in the presence of 10 mg/mL laminin-111 (LN), 20 mg/
mL galectin-3 (Gal-3) and 1 mM wortmannin (Wn), as indicated. Bars
represent mean of three independent assays done in triplicates, the SD
is also represented. Analysis was done using one-way ANOVA, followed
by the Bonferroni’s t-test for multiple comparisons. There were no
statistically significant differences among the groups treated in the
absence of galectin-3. Exposure of S12 cells to galectin-3 and laminin-
111 increased their motility about 2.5 fold over control conditions and
over exposure of laminin-111 alone (p,0.001). The galectin-3 effect was
inhibited by wortmannin (*, p,0.001), which did not affect significantly
the migratory capacity of cells under the other experimental conditions.
doi:10.1371/journal.pone.0029313.g006
Galectin-3 as a Matricellular Protein
PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e29313Figure S3 Galectin-3 expression does not alter the
expression pattern of laminin binding integrins on S12
cell surface. S12 cells were transiently transfected with the
pEf1neo (Neo) and with pEf1neo-gal-3 (Neo-Gal-3) plasmids.
After 48 hours of transfection, cells were harvested and analyzed
regarding surface expression of both a6 and b1 integrin chains
using flow cytometry. No significant differences were observed in
the integrin levels in the transfected cells.
(TIF)
Figure S4 Extracellular galectin-3 (Gal-3) decreases the
amount of phosphorylated FAK followed by extensive
reorganization of actin fibers and membrane ruffling.
The effect of exogenous galectin-3 (gal-3) on LN-induced
migration was followed either in absence or presence of lactose
(LN+gal-3 and LN+gal-3+lac, respectively) for 15 minutes. The
decrease of phosphorylated FAK (staining in green) and stress
fibers (phalloidin staining in red) in focal contacts by galectin-3 is
partially reverted in the presence of lactose as indicated by
phalloidin staining in red.
(TIF)
Figure S5 PAK is not recruited to focal adhesions in the
presence of galectin-3. S12 cells were grown on coverslips and
were subjected to the scrape assay either in the absence (ctl) or
presence of laminin-111 (LN). The effect of exogenous galectin-3
(gal-3) on LN-induced migration was followed (LN+gal-3). Cells
were fixed for 15 minutes after migration stimulus. Confocal
photomicrographs of typical fields are shown intracellular
phosphorylated PAK distribution stained in green and actin
filaments in red (labeling with rhodamine-conjugated phalloidine).
(TIF)
Figure S6 Extracellular galectin-3 increases S12 cell
migration in a dose-dependent manner. S12 cells were
grown in coverslips and subjected to the scrape assay. Migration of
S12 cells into the scratched area was measured after 24 hours by
direct counting of DAPI-stained cells using a graticle projected
onto micrographs collected using a microscope. Cells were
incubated or not in the presence of 10 mg/mL laminin-111 (LN)
and 5, 10 or 20 mg/mL galectin-3 (Gal-3), as indicated. Results are
means of two independent experiments performed in triplicate
with p,0.05 when compared migrating cells in the presence of 5
and 10 mg/mL galectin-3 and p,0.0001 when compared
migrating cells in the presence of 20 mg/mL galectin-3 with
control cells.
(TIF)
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